Bladder Cancer

Bladder Cancer

Despite symptoms such as hematuria and dysuria, doctors often miss bladder cancer among women or catch it only at an advanced stage.

A noninvasive DNA methylation test using urine samples from patients with non–muscle-invasive bladder cancer can detect cancer recurrence. The test demonstrated both specificity and sensitivity in detecting recurrence.

In an early trial, a patient with bladder cancer has had a 14-month complete response to treatment with the mTOR inhibitor everolimus.

A new study found that induction bladder-conserving treatment was safe in patients with muscle-invasive bladder cancer who achieved only a near-complete response.

As part of The Cancer Genome Atlas project, a new study aimed at understanding the molecular basis of bladder cancer has identified several potential drug targets.

A 76-year-old woman with a history of dementia, hypertension, type 2 diabetes mellitus, and newly diagnosed squamous cell carcinoma of the urinary bladder was referred to Indiana University Medical Center after 3 to 4 weeks of hospitalization at two other hospitals.

A 55-year-old woman with a history of metastatic melanoma in remission for 8 years presented to the emergency department with gross hematuria. A CT scan, ordered because the patient was in menopause, demonstrated a bladder tumor.


Subscribe to
Please Wait 20 seconds or click here to close